

Report

A Major Locus for Myoclonus-Dystonia Maps to Chromosome 7q in Eight Families

Christine Klein^{1,2} Karla Schilling,³ Rachel J. Saunders-Pullman,⁴ Jennifer Garrels,^{1,2} Xandra O. Breakefield,⁸ Mitchell F. Brin,⁵ Deborah deLeon,⁴ Dana Doheny,⁵ Stanley Fahn,⁶ J. Stephen Fink,^{8,*} Lars Forsgren,⁹ Jennifer Friedman,⁸ Steven Frucht,⁶ Juliette Harris,⁶ Gosta Holmgren,¹⁰ Bernhard Kis,¹ Roger Kurlan,¹¹ Martin Kyllerman,¹² Anthony E. Lang,¹⁴ Joanne Leung,⁸ Deborah Raymond,⁴ Janet D. Robishaw,¹⁵ Gunnar Sanner,¹⁶ Eberhard Schwinger,² Rowena E. Tabamo,⁴ Michele Tagliati,⁴ Peter Vieregge,¹ Jan Wahlström,¹³ Kristin J. Wendt,⁴ Patricia L. Kramer,³ Susan B. Bressman,⁴ and Laurie J. Ozelius⁷

Departments of ¹Neurology and ²Human Genetics, Medical University of Lübeck, Lübeck, Germany; ³Department of Neurology, Oregon Health Science University, Portland; ⁴Department of Neurology, Beth Israel Medical Center, ⁵Department of Neurology, Mount Sinai School of Medicine, ⁶Department of Neurology, Columbia University, and ⁷Molecular Genetics Department, Albert Einstein College of Medicine, New York; ⁸Molecular Neurogenetics Unit, Neurology Service, Massachusetts General Hospital, and Department of Neurology, Harvard Medical School, Boston; Departments of ⁹Neurology and ¹⁰Clinical Genetics, Umeå University, Umeå, Sweden, ¹¹Department of Neurology, University of Rochester School of Medicine, Rochester, New York; Departments of ¹²Pediatrics and ¹³Clinical Genetics, University of Gothenburg, Gothenburg, Sweden; ¹⁴Division of Neurology, Department of Medicine, University of Toronto, and the Toronto Western Hospital, Toronto; ¹⁵Henry Hood Research Program, Pennsylvania State College of Medicine, Danville; and ¹⁶Child Habilitation Centre, Central Hospital Karlstad, Karlstad, Sweden

Myoclonus-dystonia (M-D) is an autosomal dominant disorder characterized by myoclonic and dystonic muscle contractions that are often responsive to alcohol. The dopamine D2 receptor gene (*DRD2*) on chromosome 11q has been implicated in one family with this syndrome, and linkage to a 28-cM region on 7q has been reported in another. We performed genetic studies, using eight additional families with M-D, to assess these two loci. No evidence for linkage was found for 11q markers. However, all eight of these families showed linkage to chromosome 7 markers, with a combined multipoint LOD score of 11.71. Recombination events in the families define the disease gene within a 14-cM interval flanked by D7S2212 and D7S821. These data provide evidence for a major locus for M-D on chromosome 7q21.

Myoclonus-dystonia (M-D), previously known as “idiopathic hereditary myoclonus,” “hereditary essential myoclonus,” or “myoclonic dystonia” (Lang 1997 [MIM 159900]), is a rare movement disorder that is transmitted as an autosomal dominant trait with reduced penetrance. M-D usually starts in childhood or adolescence and is characterized clinically by involuntary lightning jerks (myoclonus) that respond dramatically to alcohol

and by dystonia, frequently involving the neck and arms (Mahloudji and Pikielny 1967; Quinn 1996; Gasser 1998). Because of the prominence of both myoclonus and dystonia, M-D has been grouped under the “dystonia plus” category (Fahn et al. 1998), thus differentiating it from early-onset generalized dystonia (*DYT1*) and other primary dystonias.

Previously, it was reported that a missense change (Val154Ile) in a conserved region of the D2 dopamine receptor (*DRD2*) on chromosome 11q23 cosegregated with M-D in one large family (Klein et al. 1999). However, sequence analysis of the *DRD2* gene in 17 M-D patients from other families and linkage analysis using chromosome 11 markers surrounding this gene in another four clinically similar families were negative, suggesting locus heterogeneity for this disorder (Durr et al. 2000; Klein et al. 2000). This idea was confirmed when

Received July 7, 2000; accepted for publication August 30, 2000; electronically published October 5, 2000.

Address for correspondence and reprints: Dr. Laurie J. Ozelius, AECOM, Molecular Genetics Department, 1300 Morris Park Avenue, Bronx, NY 10461. E-mail: ozelius@aecom.yu.edu

* Current affiliation: Department of Neurology, Boston University School of Medicine, Boston.

© 2000 by The American Society of Human Genetics. All rights reserved. 0002-9297/2000/6705-0029\$02.00




Figure 1 Pedigrees of families not described elsewhere in which M-D is linked to chromosome 7. An asterisk (*) denotes DNA samples, and slashes denote deceased individuals.

a second M-D locus was mapped to a 28-cM region on chromosome 7q21-q31 in a single family (Nygaard et al. 1999).

In the present study, we evaluated eight families (A–H) with M-D for linkage to the known M-D loci. In addition, two candidate genes (*GNG11* and *GNGT1*) in the chromosome 7q region were screened for mutations.

The various local IRBs approved these studies. After giving informed consent, 107 members of eight families with M-D underwent neurological examination by movement disorders specialists. Secondary myoclonus and dystonia were excluded by both history and lack of additional neurological signs in all cases and by brain imaging in selected cases. Index patients were videotaped and the tapes were reviewed by a member of the clinical team (S.B.B.) masked to pedigree and genotype status. The diagnoses of dystonia and myoclonus were established according to published criteria (Mahloudji and

Pikielny 1967; Bressman et al. 1989; Quinn 1996). Forty-two individuals were diagnosed with M-D (number of affected individuals with DNA sample, family A: 4; family B: 2; family C: 3; family D: 2; family E: 7; family F: 3; family G: 3; and family H: 18). The phenotype in these eight families is consistent with the phenotype of the families described elsewhere (Klein et al. 1999; Nygaard et al. 1999). The mean age at onset was 8.1 ± 5.9 years (range 1–37 years). Both the myoclonus and the dystonia, whether present individually or together, were most prominent in the neck and arm; other sites involved included the trunk and face. Seven of the families had at least one affected family member with known response to alcohol. Detailed clinical findings, including pedigrees, for the following families have been described elsewhere: families A and D (Klein et al. 2000), family E (Kurlan et al. 1988), and family H (Kyllerman et al. 1990). Pedigrees of the families not described else-

Table 1

Two-Point LOD Scores for Chromosome 7 Markers in M-D Families

| MARKER (LOCATION) AND FAMILY ^a | Z AT θ = | | | | | |
|---|-----------------|-------|-------|------|------|------|
| | .00 | .01 | .05 | .10 | .20 | .30 |
| D7S2204 (90.95): | | | | | | |
| A | .00 | .00 | .00 | .00 | .00 | .00 |
| B | ND | | | | | |
| C | ND | | | | | |
| D | .25 | .25 | .22 | .18 | .11 | .05 |
| E | -2.21 | -2.03 | -1.14 | -.66 | -.25 | -.09 |
| F | ND | | | | | |
| G | -2.56 | -1.11 | -.48 | -.25 | -.08 | -.03 |
| H | ND | | | | | |
| Total | -4.52 | -2.89 | -1.40 | -.73 | -.22 | -.07 |
| D7S2212 (95.43): | | | | | | |
| A | .00 | .00 | .00 | .00 | .00 | .00 |
| B | .00 | .00 | .00 | .00 | .00 | .00 |
| C | .55 | .53 | .47 | .39 | .24 | .12 |
| D | .19 | .18 | .14 | .10 | .04 | .01 |
| E | -1.88 | -.20 | .38 | .54 | .53 | .37 |
| F | .47 | .45 | .38 | .30 | .17 | .07 |
| G | .73 | .71 | .62 | .52 | .34 | .18 |
| H | 3.86 | 3.79 | 3.49 | 3.09 | 2.28 | 1.44 |
| Total | 3.92 | 5.46 | 5.48 | 4.94 | 3.60 | 2.19 |
| D7S2410 (100.81): | | | | | | |
| A | .60 | .59 | .54 | .47 | .32 | .17 |
| B | .00 | .00 | .00 | .00 | .00 | .00 |
| C | .57 | .55 | .48 | .40 | .25 | .12 |
| D | .26 | .25 | .22 | .18 | .11 | .05 |
| E | .30 | .30 | .28 | .26 | .21 | .15 |
| F | .90 | .88 | .79 | .68 | .45 | .23 |
| G | .70 | .68 | .60 | .50 | .32 | .17 |
| H | 4.84 | 4.75 | 4.39 | 3.93 | 2.94 | 1.88 |
| Total | 8.17 | 8.00 | 7.30 | 6.42 | 4.60 | 2.77 |
| D7S646 (104.86): | | | | | | |
| A | .60 | .59 | .54 | .47 | .32 | .17 |
| B | .00 | .00 | .00 | .00 | .00 | .00 |
| C | .31 | .30 | .26 | .22 | .14 | .07 |
| D | .22 | .21 | .17 | .12 | .05 | .01 |
| E | 1.82 | 1.79 | 1.66 | 1.49 | 1.13 | .73 |
| F | .78 | .76 | .69 | .59 | .39 | .20 |
| G | .70 | .68 | .60 | .50 | .32 | .17 |
| H | 4.53 | 4.44 | 4.09 | 3.64 | 2.67 | 1.63 |
| Total | 8.96 | 8.77 | 8.01 | 7.03 | 5.02 | 2.98 |
| D7S657 (104.86): | | | | | | |
| A | .00 | .00 | .00 | .00 | .00 | .00 |
| B | .00 | .00 | .00 | .00 | .00 | .00 |
| C | .15 | .14 | .12 | .10 | .06 | .03 |
| D | .22 | .21 | .17 | .12 | .05 | .01 |
| E | 1.82 | 1.79 | 1.66 | 1.49 | 1.13 | .73 |
| F | .49 | .47 | .40 | .32 | .18 | .07 |
| G | .80 | .78 | .69 | .58 | .38 | .20 |
| H | 5.17 | 5.08 | 4.71 | 4.24 | 3.22 | 2.11 |
| Total | 8.65 | 8.47 | 7.75 | 6.85 | 5.02 | 3.15 |

(continued)

where (families B, C, F, and G) are shown in figure 1. The mode of transmission was consistent with autosomal dominant inheritance with reduced penetrance in all eight families.

DNA was extracted from venous blood samples and genotyping was performed according to a standard PCR

| MARKER (LOCATION) AND FAMILY ^a | Z AT θ = | | | | | |
|---|-----------------|-------|------|------|------|------|
| | .00 | .01 | .05 | .10 | .20 | .30 |
| D7S1820 (105.92): | | | | | | |
| A | .60 | .59 | .54 | .47 | .32 | .17 |
| B | .00 | .00 | .00 | .00 | .00 | .00 |
| C | .56 | .54 | .48 | .39 | .24 | .11 |
| D | .00 | .00 | .00 | .00 | .00 | .00 |
| E | .31 | .30 | .28 | .26 | .21 | .15 |
| F | .17 | .17 | .14 | .11 | .06 | .03 |
| G | .63 | .61 | .53 | .44 | .28 | .14 |
| H | 3.93 | 3.87 | 3.59 | 3.22 | 2.41 | 1.56 |
| Total | 6.20 | 6.08 | 5.56 | 4.89 | 3.52 | 2.16 |
| D7S2482 (108.59): | | | | | | |
| A | .60 | .59 | .54 | .47 | .32 | .17 |
| B | ND | | | | | |
| C | .57 | .55 | .48 | .40 | .25 | .12 |
| D | ND | | | | | |
| E | 1.20 | 1.18 | 1.09 | .98 | .72 | .43 |
| F | .22 | .21 | .18 | .14 | .07 | .03 |
| G | .83 | .81 | .72 | .61 | .40 | .22 |
| H | .86 | .84 | .78 | .69 | .52 | .35 |
| Total | 4.28 | 4.18 | 3.79 | 3.29 | 2.28 | 1.32 |
| D7S821 (109.12): | | | | | | |
| A | .00 | .00 | .00 | .00 | .00 | .00 |
| B | ND | | | | | |
| C | .57 | .55 | .48 | .40 | .25 | .12 |
| D | .21 | .21 | .17 | .12 | .05 | .01 |
| E | 1.82 | 1.79 | 1.66 | 1.49 | 1.13 | .73 |
| F | .61 | .60 | .54 | .47 | .32 | .17 |
| G | -2.73 | -1.03 | -.41 | -.19 | -.05 | -.02 |
| H | 3.06 | 3.00 | 2.75 | 2.42 | 1.74 | 1.05 |
| Total | 3.54 | 5.12 | 5.19 | 4.71 | 3.44 | 2.06 |
| D7S1799 (113.92): | | | | | | |
| A | -3.00 | -1.39 | -.72 | -.44 | -.19 | -.08 |
| B | .30 | .29 | .26 | .22 | .13 | .06 |
| C | ND | | | | | |
| D | .23 | .22 | .18 | .13 | .05 | .01 |
| E | ND | | | | | |
| F | ND | | | | | |
| G | .68 | .66 | .58 | .48 | .30 | .16 |
| H | -2.36 | .65 | 1.74 | 1.96 | 1.75 | 1.24 |
| Total | -4.15 | .43 | 2.04 | 2.35 | 2.04 | 1.47 |

NOTE. ND = not done.

^a Map locations are based on a combination of the Marshfield Medical Research Foundation map and the Genetic Location Database.

protocol (Research Genetics), using a LICOR automated sequencer. The following markers were used on chromosome 7: D7S2204 - 4.48 cM - D7S2212 - 5.38 cM - D7S2410 - 4.05 cM - D7S646 - 0.0 cM - D7S657 - 1.06 cM - D7S1820 - 2.67 cM - D7S2482 - 0.53 cM - D7S821 - 4.80 cM - D7S1799. The following markers were used on chromosome 11: D11S2000 - 3.98 cM - D11S1391 - 0.57 cM - D11S897 - 0.00 cM - D11S1986 (*DRD2* is located between D11S1391 and D11S897/1986). Map order was obtained from the Genetic Location Database, and distances are based on the Marshfield Medical Research Foundation database.

We conducted two-point and multipoint linkage anal-




Figure 2 Multipoint LOD scores for all eight families. Markers used and their map positions are listed on the X-axis. Z_{max} is 11.71 at marker D7S646, although most of the region between D7S2212 and D7S821 reveals a LOD score >10.

yses, using the VITESSE program (O’Connell and Weeks 1995) and assuming autosomal dominant inheritance of a rare allele (frequency .0001) with reduced penetrance. Since reliable estimates of penetrance are not available for this disorder, we used an “affecteds-only” model in which only those with features of definite myoclonus, definite dystonia, or both were considered affected. All others were coded as “unknown” for disease status, and penetrance was assumed to be very low (1%). Marker allele frequencies were assumed to be equal. Two-point LOD scores were calculated for both chromosome 7 and chromosome 11 markers within the two M-D regions.

No positive linkage to the region of *DRD2* (chromosome 11q) could be demonstrated in any of these eight families (data not shown; Klein et al. 2000). However, chromosome 7 markers were consistent with linkage in all eight families (table 1), with the maximum

combined two-point LOD score (Z_{max}) at D7S646 ($Z = 8.96$ at recombination fraction $[\theta] 0.0$). Five markers that span the region, including D7S2212, D7S2410, D7S646, D7S1820, and D7S821, were used in a multipoint linkage analysis. Results are presented in figure 2 and show a maximum combined multipoint LOD score of 11.71 at D7S646. Critical crossover events that define the gene location occurred in an affected individual (family G, individual 416) and an obligate gene carrier (family E, individual 416) and are shown along with other key individuals in figure 3. Specifically, there are crossovers between D7S2212 and D7S64 in family E (D7S2410 is uninformative) and between D7S2482 and D7S821 in family G. This narrows the candidate region to a 14-cM interval between D7S2212 and D7S821 and substantially reduces the initially reported region of 28 cM (Nygaard et al. 1999). There was no shared (partial)

Table 2

Primer Pairs for Exon Amplification of *GNGT1* and *GNG11*

| GENE AND EXON | PRIMER (5'→3') | |
|----------------|------------------------|----------------------|
| | Forward | Reverse |
| <i>GNGT1</i> : | | |
| Exon 1 | CTCCAGCAATTCATGCATAG | ACTCCCACAGTATCTCTAGC |
| Exon 2 | CTGGCATCTGGAGTATTCTG | CACGTACATGCTTAGTAGTA |
| <i>GNG11</i> : | | |
| Exon 1 | GCCTTCAGTTGTTTCGGGA | CAGGAAAAATCGGACCCTGC |
| Exon 2 | CATTAAGGCGTAGGGACAAAAG | AGTGAGCAAAGATGAGTAGC |




Figure 3 Partial pedigrees for the families possessing critical recombination events. The shaded chromosomes are the disease-bearing chromosomes. In family E, individual 416 has a crossover between D7S2212 and D7S646, with D7S2410 being uninformative. In family G, individual 416 has a recombination between D7S821 and D7S1820. Taken together, these crossovers place the M-D locus between D7S2212 and D7S821, an interval of ~14 cM. The distances between markers are given in the text.

haplotype within the linked region across families, rendering a recent common founder mutation unlikely.

Large parts of the chromosome 7q region have already been sequenced and well characterized (Bouffard et al. 1997), thereby facilitating the search for candidate genes. On the basis of the apparent involvement of *DRD2* in one family with M-D, the two gamma subunits of guanine nucleotide-binding proteins (G-proteins *GNG11* and *GNGT1*) that are located in this region of chromosome 7 (National Center for Biotechnology Information accession number AC002076) represented appealing candidates for mutation screening. G proteins are involved as modulators or transducers in various transmembrane signaling systems and thus could interact with the dopamine D2 receptor in second messenger pathways.

We designed primer pairs to allow bidirectional sequencing of the two exons of each gene (table 2). Genomic DNA from one affected member of each family or from control individuals was amplified using standard PCR conditions. Dideoxy cycle sequencing of PCR products was performed with the Thermo Sequenase Fluor Primer Cycle Sequencing Kit (Amersham). No mutations were found in the coding regions of these two genes in any of the families. However, in *GNGT1*, a G→A tran-

sition at base pair 148 (E50K) was detected in families E, H, and C. When other affected members of these families were typed, this change was not inherited with the disease. In addition, this same variation was seen in control individuals. Both of these findings suggest that the E50K change is a polymorphism. Previously, Nygaard et al. (1999) excluded sequence alterations in the gene for the human metabotropic glutamate receptor type 3 (*GRM3*) in another family with M-D linked to 7q. Since the candidate region is still quite large and contains many genes, linkage studies, currently in progress, of additional families with M-D and identification of more markers in the region will be needed for further fine mapping of this locus.

Acknowledgments

We thank all the patients and family members who participated in these studies for providing samples and inspiration. This work was supported by funds from the Myoclonus Research Foundation (to L.O. and S.F.), the Dystonia Medical Research Foundation (to L.O., X.O.B., S.B., R.S.P., D.dL., D.R., and P.K.), the Fritz Thyssen Stiftung (to C.K., B.K., and P.V.), the Deutsche Forschungsgemeinschaft (to C.K. and P.V.),

and the Bachmann-Strauss Dystonia and Parkinson Foundation (to M.B. and D.D.) and by NIH grants NS28384 (to X.O.B.) and NS26656 (to S.B., L.O., P.K., R.S.P., and D.R.).

Electronic-Database Information

Accession numbers and URLs for data in this article are as follows:

Center for Medical Genetics, Marshfield Medical Research Foundation, <http://research.marshfieldclinic.org/genetics/>
Genetic Location Database, http://cedar.genetics.soton.ac.uk/public_html/lldb.html

National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/>

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for M-D [MIM 159900])

References

- Bouffard GG, Idol JI, Braden VV, Iyer LM, Cunningham AF, Weintraub LA, Touchman JW, Mohr-Tidwell RM, Peluso DC, Fulton RS, Ueltzen MS, Weissenbach J, Magness CL, Green ED (1997) A physical map of human chromosome 7: an integrated YAC contig map with average STS spacing of 79 kb. *Genome Res* 7:673–692
- Bressman SB, de Leon D, Brin MF, Risch N, Burke RE, Greene PE, Shale H, Fahn S (1989) Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. *Ann Neurol* 26:612–620
- Durr A, Tassin J, Vidailhet M, Durif F, Jedynak P, Agid Y, Brice A (2000) D2 dopamine receptor gene in myoclonic dystonia and essential myoclonus. *Ann Neurol* 48:127–128
- Fahn S, Bressman SB, Marsden CD (1998) Classification of dystonia. *Adv Neurol* 78:1–10
- Gasser T (1998) Inherited myoclonus-dystonia syndrome. *Adv Neurol* 78:325–334
- Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ (1999) Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. *Proc Natl Acad Sci USA* 96:5173–5176
- Klein C, Gurvich N, Sena-Esteves M, Bressman S, Brin MF, Ebersole BJ, Fink S, Forsgren L, Friedman J, Grimes D, Holmgren G, Kyllerman M, Lang AE, de Leon D, Leung J, Prioleau C, Raymond D, Sanner G, Saunders-Pullman R, Vieregge P, Wahlstrom J, Breakefield XO, Kramer PL, Ozelius LJ, Sealfon SC (2000) Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. *Ann Neurol* 47:369–373
- Kurlan R, Behr J, Medved L, Shoulson I (1988) Myoclonus and dystonia: a family study. *Adv Neurol* 50:385–389
- Kyllerman M, Forsgren L, Sanner G, Holmgren G, Wahlstrom J, Drugge U (1990) Alcohol-responsive myoclonic dystonia in a large family: dominant inheritance and phenotypic variation. *Mov Disord* 5:270–279
- Lang AE (1997) Essential myoclonus and myoclonic dystonia. *Mov Disord* 12:127
- Mahloudji M, Pikielny RT (1967) Hereditary essential myoclonus. *Brain* 90:669–674
- Nygaard TG, Raymond D, Chen C, Nishino I, Greene PE, Jennings D, Heiman GA, Klein C, Saunders-Pullman RJ, Kramer P, Ozelius LJ, Bressman SB (1999) Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. *Ann Neurol* 46:794–798
- O'Connell JR, Weeks DE (1995) The VITESSE algorithm for rapid exact multilocus linkage analysis via genotype set—recording and fuzzy inheritance. *Nat Genet* 11:402–408
- Quinn NP (1996) Essential myoclonus and myoclonic dystonia. *Mov Disord* 11:119–124